Resistance mutation info of drug
| Drug General Information | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug ID | D0ML1F | |||||||||||||||
| Drug Name | Adefovir Dipivoxil | |||||||||||||||
| Synonyms | Adefovirdipivoxl; Hepsera; Preveon; YouHeDing; Adefovir depivoxil; Adefovir pivoxil; GS 0840; GS 840;Piv2PMEA; Adefovir dipivoxil (USAN); Adefovir pivoxil (JAN); Bis(pom)PMEA; Bis-POM PMEA; GS-0840; GS-840; Hepsera (TM); Hepsera (TN); Preveon (TN); Bis(POM)-PMEA; Bis-POM PMEA, Adefovir Dipivoxil; Bis-POM PMEA, Preveon, Hepsera, Adefovir Dipivoxil; Bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine; [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; Propanoic acid,2,2-dimethyl-(((2-(6-amino-9H-purin-9-yl)ehtoxy)mehtyl)phosphinyldiene)bis(oxymehtylene)ester; Propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) ester; (((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) 2,2-dimethylpropanoate; ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid, diester with hydroxymethyl pivalate; 9-(2-((-Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; 9-(2-((Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; ADV | |||||||||||||||
| Drug Type | Small molecular drug | |||||||||||||||
| Therapeutic Class | Antiviral Agents | |||||||||||||||
| Company | Gilead Sciences | |||||||||||||||
| Structure |
|
|||||||||||||||
| Drug Resistance Mutations | ||||||||||||||||
| Target Name | HBV Reverse transcriptase | Target Info | ||||||||||||||
| Uniprot ID | DPOL_HBVB5(347-690) | |||||||||||||||
| Species | Hepatitis B virus genotype B (HBV-B) | |||||||||||||||
| Reference Sequence |
EDWGPCTEHGEHRIRTPRTPARVTGGVFLVDKNPHNTTESRLVVDFSQFSRGNTRVSWPK FAVPNLQSLTNLLSSNLSWLSLDVSAAFYHLPLHPAAMPHLLVGSSGLSRYVARLSSNSR IINNQHRTMQNLHNSCSRNLYVSLMLLYKTYGRKLHLYSHPIILGFRKIPMGVGLSPFLL AQFTSAICSVVRRAFPHCLAFSYMDDVVLGAKSVQHLESLYAAVTNFLLSLGIHLNPHKT KRWGYSLNFMGYVIGSWGTLPQEHIVQKIKMCFRKLPVNRPIDWKVCQRIVGLLGFAAPF TQCGYPALMPLYACIQAKQAFTFSPTYKAFLSKQYLNLYPVARQ [Hepatitis B vi rus genotype B (HBV-B)] |
|||||||||||||||
| Targeted Disease | HBV infection | |||||||||||||||
| Drug Resistance Mutations |
|
|||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
| References | ||||||||||||||||
| REF 1 | Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients. Antivir Ther. 2014;19(6):551-8. | |||||||||||||||
| REF 2 | Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China. Microb Drug Resist. 2017 Jun;23(4):516-522. | |||||||||||||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.